WHAT PEOPLE SAY AND WHAT STUDIES SHOW
Reports about GHK-Cu do not prove what caused a change
In GHK-Cu, a skin-care ingredient holds copper on a small chain. This page separates personal accounts from trials and lists reasons for care.
Small skin studies cannot settle the risks of GHK-Cu shots
Three linked protein parts carry copper in GHK-Cu. Here you can compare personal accounts with the limits of the studies. Reports mention a firmer feel, shallower lines, added moisture, and hair that looks thicker. A personal account can't show that GHK-Cu caused any of those changes.
Sensitive skin can itch, dry out, or turn red. The body uses copper to make melanin, the substance that gives skin its brown color. People who get dark spots may have added reason for care. Strong acids and strong vitamin C can also pull copper from the chain. A disease that affects copper in the body raises a separate concern about whole-body use.
A personal report can't diagnose you or set a rule for care.
The human skin studies are small. Human studies have not shown how the body handles GHK-Cu shots. The words below describe how often a claim appeared in reports. They do not give your chance of having the same result.
People report wanted changes as well as skin trouble
People using GHK-Cu gave these accounts. They are not controlled-trial findings, and no trial has measured how often the events happen.
Changes people wanted
A firmer or tighter feel. This appears very often in reports, and users describe some spring returning slowly. What someone feels is not a measured result.
Softer lines and less-deep wrinkles. This appears very often, with users usually describing a slow change. Two photographs can't prove the cause.
Less dryness and a fuller look. This appears often, and some users notice less dryness before added firmness. The account describes appearance and feel; no skin test was done.
A smoother surface and brighter color. This appears often, with people describing skin that feels smoother and looks fresher. No controlled trial has checked these accounts.
Marks that fade or color that looks more even. This appears now and then, yet other people say dark spots grew worse. The mixed accounts do not show what GHK-Cu caused.
Less redness near a scar or after a skin procedure. This appears now and then, with people mentioning less redness or a changed scar. Their accounts can't show faster healing.
Less hair loss or a thicker look. This appears often, but many people used other hair products too. The cause remains unknown.
Skin or body changes after research shots. This appears now and then among a smaller group describing skin or recovery after shots. Human trials haven't supported the claims.
Changes people did not want
Itching, dry skin, or redness. This appears often, mostly among people with sensitive skin. A guess about the cause can't replace sound safety facts.
Pimples soon after starting a product. This appears now and then, and some people call it a brief clearing spell. A lasting or painful rash may be irritation; no trial has confirmed a clearing effect.
Skin that looks duller or older. This appears rarely, and some accounts use the nickname “copper uglies.” The name does not describe a known medical reaction.
More irritation with strong skin products. This appears often, and users may suspect strong acids, vitamin C, or retinol. Their accounts can't prove which item caused it.
Darker spots or uneven color for a time. This appears rarely among people who already had dark spots. They describe darker or patchy areas, but the reports do not prove a cause.
Bruising, burning, stinging, swelling, or redness after a shot. This appears now and then in accounts of unproved research use, not usual skin care.
Shots, copper problems, and skin reactions call for care
Care group — Systemic use has no validated human basis. Topical Copper Tripeptide-1 has a cosmetic record, but injectable and systemic GHK-Cu remain unapproved and unstudied in humans. The nearest pharmacokinetic evidence is a rat study showing rapid breakdown of free GHK in plasma. [17]
Care group — Copper balance is a theoretical systemic concern. Theoretical caution. Repeated systemic copper exposure could, in principle, disturb copper and zinc balance, with special relevance to copper-handling conditions such as Wilson's disease. No published GHK-Cu toxicity case establishes this; it is theoretical and does not describe ordinary topical use.
Care group — Pigment can plausibly move in the wrong direction. Copper supports tyrosinase, an enzyme involved in making melanin. A cell study found increased tyrosinase activity and melanin with a copper peptide, so darker pigment is a preclinical possibility, not a proven human outcome. [18]
Care group — Sensitive skin can react. Redness, itching, and dryness appear in topical reports. A small controlled post-laser study found no objective redness difference, while satisfaction favored the copper-peptide group; tolerability can still differ. [19]
Care group — A product page is not a prescribing decision. GHK-Cu prescription care is one service at mypromise.com, where Promise Peptides now prescribes the injectable. A clinician holding a U.S. license studies each patient's case and can decline to prescribe. This service sees U.S. patients alone; the state and requested treatment set further limits. The GHK-Cu medicine is compounded and has no FDA approval.
Care group — Low-pH actives can destabilize the complex. Ascorbic acid at low pH and strong exfoliating acids can disrupt the copper-peptide complex and add irritation. Delivery research places the intact peptide in a milder pH range. [15]
Care group — The copper-bound form matters. Free GHK did not reproduce the copper complex's MMP-2 response in fibroblast cultures. A degraded product or different peptide form cannot be assumed to behave like intact GHK-Cu. [21]
Care group — Loose copper can become pro-oxidant. Intact GHK-Cu binds copper tightly and limits its reactivity. If the complex breaks apart, that protection is lost and free copper can promote oxidation. [20]
Care group — The human record is narrow. The best human evidence comes from small topical skin and hair studies. Broader gene, anti-aging, and systemic claims lean on cells, animals, database work, and a concentrated investigator record. [15] [3]
Long use in cosmetics does not make GHK-Cu an approved drug
Loren Pickart's work with human blood first brought GHK to notice in 1973. Reviews later placed blood GHK near 200 billionths of one gram for every milliliter of blood at age 20. They placed it near 80 billionths of one gram for each milliliter by age 60 [3]. That fall is not a blood-test goal and does not prove that treatment is needed. GHK-Cu later took the name Copper Tripeptide-1 in skin creams and serums [6] [15]. Its long cosmetic use does not give it approval as a drug.